Molecular Diagnostic Yield and Safety Profile of Ultrasound-Guided Lung Biopsies: A Cross-Sectional Study

• Published in: Cancers Vol. 16; no. 16; p. 2860
• Main Authors: D'Agnano, Vito, Perrotta, Fabio, Stella, Giulia Maria, Pagliaro, Raffaella, De Rosa, Filippo, Cerqua, Francesco Saverio, Schiattarella, Angela, Grella, Edoardo, Masi, Umberto, Panico, Luigi, Bianco, Andrea, Iadevaia, Carlo
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.08.2024; MDPI
• Subjects: Adenocarcinoma; Biopsy; Bronchoscopy; Cancer therapies; Computed tomography; Diagnosis; Diagnosis, Ultrasonic; Immunohistochemistry; Invasiveness; Iodine; Lesions; Lung cancer; Lungs; Lymphoma; Malignancy; Metastasis; Morphology; Next-generation sequencing; Non-small cell lung carcinoma; pathology; Patients; PD-L1; PD-L1 protein; Pneumonia; Pneumothorax; Precision medicine; Squamous cell carcinoma; Stains & staining; Ultrasonic imaging; Ultrasound; Italy; United States > US; lung cancer; targeted therapy; pathology; PD-L1; biopsy; diagnosis; ultrasound
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16162860

The recent advances in precision oncology for lung cancer treatment has focused attention on the importance of obtaining appropriate specimens for tissue diagnosis as well as comprehensive molecular profiling. CT scan-guided biopsies and bronchoscopy are currently the main procedures employed for tissue sampling. However, growing evidence suggests that ultrasound-guided biopsies may represent an effective as well as safe approach in this diagnostic area. This study explores the safety and the diagnostic yield for cancer molecular profiling in ultrasound-guided percutaneous lung lesion biopsies (US-PLLB). One hundred consecutive patients with suspected lung cancer, between January 2021 and May 2024, who had ultrasound-guided lung biopsies have been retrospectively analyzed. Molecular profiling was conducted with next-generation sequencing Genexus using Oncomine precision assay or polymerase chain reaction according to specimen quality. Qualitative immunohistochemical assay of programmed death ligand 1 (PD-L1) expression was evaluated by the Dako PD-L1 immunohistochemistry 22C3 pharmDx assay. The co-primary endpoints were the molecular diagnostic yield and the safety profile of US-guided lung biopsies. From January 2021 to May 2024, 100 US-guided lung biopsies were carried out and 95 were considered for inclusion in the study. US-PLLB provided informative tissue for a histological evaluation in 93 of 95 patients with an overall diagnostic accuracy of 96.84% [Sensitivity: 92.63%; Specificity: 96.84%; PPV: 100%; NPV: 100%]. Sixty-Six patients were diagnosed with NSCLC (69.47%) and were considered for molecular diagnostic yield evaluation and PD-L1 testing. Four patients had malignant lymphoid lesions. US-PLLB was not adequate to achieve a final diagnosis in three patients (3.16%). Complete molecular profiling and PD-L1 evaluation were achieved in all patients with adenocarcinoma (molecular diagnostic yield: 100%). PD-L1 evaluation was achieved in 28 of 29 patients (96.55%) with either SCC or NOS lung cancer. The overall complication rate was 9.47% (n = 9). Six patients (6.31%) developed pneumothorax, while three patients (3.16%) suffered mild haemoptysis without desaturation. According to our findings, US-guided lung biopsy is a safe, minimally invasive procedure in patients with suspected lung malignancies, providing an excellent diagnostic yield for both comprehensive molecular profiling and PD-L1 testing. In addition, our results suggest that US-guided biopsy may also be an effective diagnostic approach in patients with suspected lung lymphoma.